Ekta Gupta1, Pragya Agarwala2, Guresh Kumar2, Rakhi Maiwall2, Shiv Kumar Sarin2. 1. Department of Clinical Virology, Institute of Liver & Biliary Sciences (ILBS), Vasant Kunj, New Delhi 110070, India. Electronic address: ektagaurisha@gmail.com. 2. Department of Clinical Virology, Institute of Liver & Biliary Sciences (ILBS), Vasant Kunj, New Delhi 110070, India.
Abstract
BACKGROUND: Molecular testing at the point-of-care may turn out to be game changer for HCV diagnosis and treatment monitoring, through increased sensitivity, reduced turnaround time, and ease of performance. One such assay GeneXpert® has recently been released. OBJECTIVES: Comparative analysis between performances of GeneXpert® and Abbott HCV-RNA was done. STUDY DESIGN: 174 HCV infected patients were recruited and, one time plasma samples from 154 patients and repeated samples from 20 patients, obtained at specific treatment time-points (0, 4, 12 and 24) weeks were serially re-tested on Xpert®. RESULTS: Genotype 3 was the commonest, seen in 80 (66%) of the cases, genotype 1 in 34 (28.3%), genotype 4 in 4 (3.3%) and genotypes 2 and 5 in 1 (0.8%) each. Median HCV RNA load was 4.69 log10 (range: 0-6.98log10) IU/ml. Overall a very good correlation was seen between the two assays (R2=0.985), concordance of the results between the assays was seen in 138 samples (89.6%). High and low positive standards were tested ten times on Xpert® to evaluate the precision and the coefficient of variation was 0.01 for HPC and 0.07 for the LPC. Monitoring of patients on two different regimes of treatment, pegylated interferon plus ribavirin and sofosbuvir plus ribavirin was done by both the systems at baseline, 4, 12 and 24 weeks. Perfect correlation between the assays in the course of therapy at different treatment time- point in genotypes 3 and 1 was seen. CONCLUSION: The study demonstrates excellent performance of the Xpert® HCV assay in viral load assessment and in treatment course monitoring consistency.
BACKGROUND: Molecular testing at the point-of-care may turn out to be game changer for HCV diagnosis and treatment monitoring, through increased sensitivity, reduced turnaround time, and ease of performance. One such assay GeneXpert® has recently been released. OBJECTIVES: Comparative analysis between performances of GeneXpert® and Abbott HCV-RNA was done. STUDY DESIGN: 174 HCV infectedpatients were recruited and, one time plasma samples from 154 patients and repeated samples from 20 patients, obtained at specific treatment time-points (0, 4, 12 and 24) weeks were serially re-tested on Xpert®. RESULTS: Genotype 3 was the commonest, seen in 80 (66%) of the cases, genotype 1 in 34 (28.3%), genotype 4 in 4 (3.3%) and genotypes 2 and 5 in 1 (0.8%) each. Median HCV RNA load was 4.69 log10 (range: 0-6.98log10) IU/ml. Overall a very good correlation was seen between the two assays (R2=0.985), concordance of the results between the assays was seen in 138 samples (89.6%). High and low positive standards were tested ten times on Xpert® to evaluate the precision and the coefficient of variation was 0.01 for HPC and 0.07 for the LPC. Monitoring of patients on two different regimes of treatment, pegylated interferon plus ribavirin and sofosbuvir plus ribavirin was done by both the systems at baseline, 4, 12 and 24 weeks. Perfect correlation between the assays in the course of therapy at different treatment time- point in genotypes 3 and 1 was seen. CONCLUSION: The study demonstrates excellent performance of the Xpert® HCV assay in viral load assessment and in treatment course monitoring consistency.
Authors: Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely Journal: Liver Int Date: 2018-09-22 Impact factor: 5.828
Authors: Liza Coyer; Oudou Njoya; Richard Njouom; Tatiana Mossus; Mathurin Pierre Kowo; Frida Essomba; Alexander Boers; Roel Coutinho; Pascale Ondoa Journal: Trop Med Int Health Date: 2020-07-05 Impact factor: 2.622
Authors: Alba Llibre; Yusuke Shimakawa; Matthew L Albert; Darragh Duffy; Estelle Mottez; Shaun Ainsworth; Tan-Phuc Buivan; Rick Firth; Elliott Harrison; Arielle R Rosenberg; Jean-François Meritet; Arnaud Fontanet; Pablo Castan; Antonio Madejón; Mark Laverick; Allison Glass; Raquel Viana; Stanislas Pol; C Patrick McClure; William Lucien Irving; Gino Miele Journal: Gut Date: 2018-04-03 Impact factor: 23.059
Authors: Nick Scott; Thin Mar Win; Tom Tidhar; Hla Htay; Bridget Draper; Phyo Thu Zar Aung; Yinzong Xiao; Anna Bowring; Christian Kuschel; Sonjelle Shilton; Khin Pyone Kyi; Win Naing; Khin Sanda Aung; Margaret Hellard Journal: Lancet Reg Health West Pac Date: 2021-03-23